MBC Connect 2.0 is an interactive, web and mobile-friendly, patient experience registry where you can share information about your MBC disease history, experiences, and quality of life – and now, get potential matches to clinical trials. Join today, or update your app to access the latest features.
NEW YORK, Oct. 23, 2019 /PRNewswire/ — A retrospective analysis – reported in the journal Cancer by Judith Malmgren, PhD, and co-authors – studied patients in the Surveillance, Epidemiology, and End Results (SEER) 9 population and an institutional cohort with de novo metastatic breast cancer (MBC), which is a first diagnosis of breast cancer that is stage IV. The SEER 9 population includes cancer patients in nine US regions including Seattle-Puget Sound, and is representative of the US population. The institutional cohort includes patients with breast cancer who are followed over time, who live in the Seattle-Puget Sound registry area, and whose cases are included in SEER Seattle-Puget Sound. Approximately 13,000 new cases of de novo MBC are diagnosed annually in the United States.
VISIT
to raise awareness of metastatic breast cancer!
